Carlyle Group Inc. Makes New Investment in Q32 Bio Inc. $QTTB

Carlyle Group Inc. acquired a new stake in shares of Q32 Bio Inc. (NASDAQ:QTTB) during the second quarter, Holdings Channel reports. The firm acquired 60,363 shares of the company’s stock, valued at approximately $769,000. Q32 Bio accounts for approximately 0.0% of Carlyle Group Inc.’s holdings, making the stock its 13th largest position.

Several other large investors also recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Q32 Bio by 107.7% in the 1st quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock worth $1,328,000 after buying an additional 107,315 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in Q32 Bio by 75.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock valued at $225,000 after buying an additional 15,000 shares in the last quarter. HRT Financial LP grew its position in Q32 Bio by 66.5% in the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after acquiring an additional 9,862 shares during the period. Goldman Sachs Group Inc. grew its position in Q32 Bio by 140.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after acquiring an additional 25,953 shares during the period. Finally, Jane Street Group LLC acquired a new position in Q32 Bio during the second quarter worth $69,000. 31.32% of the stock is currently owned by institutional investors.

Q32 Bio Stock Up 5.3%

Q32 Bio stock opened at $15.95 on Tuesday. The stock has a 50-day simple moving average of $14.29 and a 200 day simple moving average of $9.00. The stock has a market capitalization of $474.83 million, a price-to-earnings ratio of 5.32 and a beta of 0.23. Q32 Bio Inc. has a 12-month low of $1.62 and a 12-month high of $23.57.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. As a group, sell-side analysts anticipate that Q32 Bio Inc. will post -1.53 EPS for the current year.

Wall Street Analysts Forecast Growth

QTTB has been the topic of a number of recent analyst reports. Oppenheimer boosted their price target on shares of Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. HC Wainwright raised their price objective on shares of Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Cantor Fitzgerald initiated coverage on shares of Q32 Bio in a research note on Monday, May 18th. They issued an “overweight” rating for the company. Zacks Research downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Finally, Mizuho started coverage on Q32 Bio in a research report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc bought 1,875,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was bought at an average price of $8.00 per share, for a total transaction of $15,000,000.00. Following the completion of the transaction, the director directly owned 3,502,987 shares in the company, valued at $28,023,896. The trade was a 115.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Diyong Xu purchased 1,875,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director directly owned 3,502,987 shares of the company’s stock, valued at $28,023,896. This trade represents a 115.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 34.46% of the stock is currently owned by company insiders.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.